- Home
- BMA vs MIRM Comparison
BMA vs MIRM Comparison
Compare BMA & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMA
- MIRM
- Stock Information
- Founded
- BMA 1966
- MIRM 2018
- Country
- BMA Argentina
- MIRM United States
- Employees
- BMA N/A
- MIRM N/A
- Industry
- BMA Commercial Banks
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- BMA Finance
- MIRM Health Care
- Exchange
- BMA Nasdaq
- MIRM Nasdaq
- Market Cap
- BMA 4.2B
- MIRM 3.8B
- IPO Year
- BMA 2006
- MIRM 2019
- Fundamental
- Price
- BMA $57.61
- MIRM $69.99
- Analyst Decision
- BMA Buy
- MIRM Strong Buy
- Analyst Count
- BMA 6
- MIRM 11
- Target Price
- BMA $73.50
- MIRM $79.00
- AVG Volume (30 Days)
- BMA 759.2K
- MIRM 609.1K
- Earning Date
- BMA 11-26-2025
- MIRM 11-11-2025
- Dividend Yield
- BMA 2.46%
- MIRM N/A
- EPS Growth
- BMA N/A
- MIRM N/A
- EPS
- BMA 0.50
- MIRM N/A
- Revenue
- BMA $2,573,406,817.00
- MIRM $429,161,000.00
- Revenue This Year
- BMA N/A
- MIRM $53.14
- Revenue Next Year
- BMA $3.01
- MIRM $19.83
- P/E Ratio
- BMA $12.22
- MIRM N/A
- Revenue Growth
- BMA N/A
- MIRM 62.33
- 52 Week Low
- BMA $38.30
- MIRM $36.88
- 52 Week High
- BMA $118.42
- MIRM $78.55
- Technical
- Relative Strength Index (RSI)
- BMA 63.24
- MIRM 42.93
- Support Level
- BMA $51.35
- MIRM $66.99
- Resistance Level
- BMA $56.57
- MIRM $70.71
- Average True Range (ATR)
- BMA 3.60
- MIRM 2.68
- MACD
- BMA 1.38
- MIRM -0.74
- Stochastic Oscillator
- BMA 86.94
- MIRM 25.96
About BMA Banco Macro S.A. ADR (representing Ten Class B)
Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. It generates the majority of its revenue from Argentina.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.